Inspirna, Inc.   Report issue

For profit Phase 1 Phase 2
Founded: New York NY United States (2010)
Status: Left NME R&D (2023)

Organization Overview

First Clinical Trial
2016
NCT02922764
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Inspirna, Inc. | Rgenix, Inc.